Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Atara Biotherapeutics (ATRA) over the last 4 years, with Q1 2025 value amounting to $300000.0.

  • Atara Biotherapeutics' Depreciation and Depletion fell 6666.67% to $300000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $800000.0, marking a year-over-year decrease of 7419.35%. This contributed to the annual value of $2.7 million for FY2024, which is 2702.7% down from last year.
  • Atara Biotherapeutics' Depreciation and Depletion amounted to $300000.0 in Q1 2025, which was down 6666.67% from $500000.0 recorded in Q4 2024.
  • In the past 5 years, Atara Biotherapeutics' Depreciation and Depletion ranged from a high of $1.5 million in Q1 2022 and a low of $300000.0 during Q1 2025
  • For the 4-year period, Atara Biotherapeutics' Depreciation and Depletion averaged around $884615.4, with its median value being $900000.0 (2022).
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first changed by 0.0% in 2023, then plummeted by 6666.67% in 2025.
  • Atara Biotherapeutics' Depreciation and Depletion (Quarter) stood at $900000.0 in 2022, then changed by 0.0% to $900000.0 in 2023, then plummeted by 44.44% to $500000.0 in 2024, then plummeted by 40.0% to $300000.0 in 2025.
  • Its last three reported values are $300000.0 in Q1 2025, $500000.0 for Q4 2024, and $600000.0 during Q3 2024.